Contact
Please use this form to send email to PR contact of this press release:
Iovance Biotherapeutics Announces Approval of First Clinical Trial Application by Competent Authority in Netherlands for a Phase 2 Trial of LN-145 for the Treatment of Patients with Cervical Cancer
TO: